Related Experiment Video
Updated: Jun 7, 2026
12:33
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Incretin therapy for type 2 diabetes mellitus
1Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, CA 94401, USA. dklonoff@yahoo.com
Advances in Therapy
|October 28, 2010
Summary
Abnormalities in the incretin system are key defects in type 2 diabetes. Incretin-based agents address these fundamental mechanisms, improving hyperglycemia and cardiovascular risk factors.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus involves pancreatic beta-cell failure, insulin resistance, and incretin hormone abnormalities.
- Current treatments often fail to address all underlying defects and may worsen cardiovascular risk factors.
- Incretin system dysfunction is a critical factor in type 2 diabetes pathophysiology.
Purpose of the Study:
- To review the role of incretin system defects in type 2 diabetes.
- To discuss advances in incretin-based therapies targeting core disease mechanisms.
Main Methods:
- Literature review of incretin system pathophysiology in type 2 diabetes.
- Analysis of incretin-based agents and their impact on disease mechanisms and cardiovascular risk markers.
Main Results:
- Incretin-based agents effectively reduce hyperglycemia.
- These agents demonstrate beneficial effects on cardiovascular risk markers such as weight, blood pressure, and lipid profiles.
- Incretin-based therapies target fundamental pathophysiological defects in type 2 diabetes.
Conclusions:
- Incretin-based agents offer a targeted approach to managing type 2 diabetes by addressing key pathophysiological defects.
- These therapies provide dual benefits of glycemic control and cardiovascular risk reduction.
- Aligning treatment with disease mechanisms, including incretin function, is crucial for effective type 2 diabetes management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...